ClinicalTrials.gg

Program

riliprubart

Also written as “Riliprubart”, “Riliprubart Prefilled Pen (PFP)” and “BIVV020 (SAR445088)”.

In Sanofi's pipeline, C1s mAb. Its studies are mostly in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Anemia, Hemolytic, Autoimmune · Purpura, Thrombocytopenic, Idiopathic, led by Sanofi.

Furthest: phase 3, since Feb 26, 20248 company-led studies, 4 open or runningNext primary completion: Jul 9, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi84 open or runningphase 3since Feb 26, 2024Jan 29, 2020Jul 9, 2027phase 3 · NCT06290141
  • Named in Sanofi’s own pipeline as riliprubart, phase 3, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 29, 2020First study: phase 1 study in Anemia, Hemolytic, AutoimmuneFirst studyNCT04269551 · 12 enrolled · United States, Germany, Italy and more
  2. Dec 1, 20202 phase 2 studiesNCT04658472, NCT04669600
  3. Mar 15, 2021Phase 1 study in Anemia, Hemolytic, AutoimmuneNCT04802057 · 9 enrolled · Germany, Italy, Netherlands and more
  4. Nov 18, 2021Phase 2 study in Transplant RejectionNCT05156710 · 48 enrolled · United States, Canada, France and more
  5. Feb 26, 20242 phase 3 studies in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT06290141, NCT06290128
  6. Feb 27, 2025Phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT06859099 · 300 planned · United States, Argentina, Brazil and more

Ahead

  1. Jul 9, 2027Primary completion: phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT06290141
  2. Oct 3, 2029Primary completion: phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT06859099

TargetBeta

“C1s mAb”the company's pipeline, read by Claude · source

Other programs on C1S

ProgramCompanyFurthest phaseStudies
SAR446597Sanofiphase 21
RAY121Hoffmann-La Rochephase 12

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06859099Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Brazil and more3By invitationOct 3, 2029300
NCT06290141Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Belgium and more3RecruitingJul 9, 2027160
NCT06290128Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Belgium and more3Active, not recruitingJun 10, 2026109
NCT05156710Transplant Rejection · United States, Canada, France and more2Active, not recruitingOct 21, 202548
NCT04802057Anemia, Hemolytic, Autoimmune · Germany, Italy, Netherlands and more1TerminatedMar 4, 20259
NCT04669600Purpura, Thrombocytopenic, Idiopathic · United States, Czechia, Germany and more2CompletedFeb 15, 202212
NCT04658472Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Canada, China and more2CompletedOct 1, 202598
NCT04269551Anemia, Hemolytic, Autoimmune · United States, Germany, Italy and more1CompletedJan 6, 202212

How it is read

Names in the registry

  • “riliprubart”, 2 entries
  • “Riliprubart”, 2 entries
  • “Riliprubart Prefilled Pen (PFP)”, 1 entry
  • “BIVV020 (SAR445088)”, 1 entry
  • “SAR445088 (IV)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.